Silo Pharma Initiates SPC-15 Robustness Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 29 2026
0mins
Source: Newsfilter
- Study Initiation: Silo Pharma has engaged Resyca to conduct a robustness study evaluating the performance and formulation stability of its microchip-based nasal spray system for SPC-15, laying the groundwork for upcoming human clinical trials.
- FDA Meeting Preparation: The data from this study is expected to support Silo Pharma's Type C meeting request with the FDA, seeking regulatory guidance on its IND strategy and Phase 1 clinical trial design, thereby advancing the product development process.
- Technological Advantage: Resyca's patented Soft-Mist Nasal Spray system is designed to effectively bypass the blood-brain barrier, and Silo believes this technology could enhance drug concentrations in the brain while reducing systemic exposure, potentially accelerating therapeutic onset and improving safety.
- Standard Testing: Robustness testing is a standard component of combination product development, and Silo's study will assess the formulation stability and device performance consistency of SPC-15 and its placebo over a 30-day period to ensure reliability before clinical evaluation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SILO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SILO
About SILO
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Silo Pharma Initiates SPC-15 Robustness Study
- Study Initiation: Silo Pharma has engaged Resyca to conduct a robustness study evaluating the performance and formulation stability of its microchip-based nasal spray system for SPC-15, laying the groundwork for upcoming human clinical trials.
- FDA Meeting Preparation: The data from this study is expected to support Silo Pharma's Type C meeting request with the FDA, seeking regulatory guidance on its IND strategy and Phase 1 clinical trial design, thereby advancing the product development process.
- Technological Advantage: Resyca's patented Soft-Mist Nasal Spray system is designed to effectively bypass the blood-brain barrier, and Silo believes this technology could enhance drug concentrations in the brain while reducing systemic exposure, potentially accelerating therapeutic onset and improving safety.
- Standard Testing: Robustness testing is a standard component of combination product development, and Silo's study will assess the formulation stability and device performance consistency of SPC-15 and its placebo over a 30-day period to ensure reliability before clinical evaluation.
See More
Silo Pharma Regains Nasdaq Compliance
- Compliance Regained: Silo Pharma announced on June 17 that it has regained compliance with Nasdaq's minimum bid price requirement, allowing its shares to continue trading on the Nasdaq Capital Market, which enhances investor confidence and stabilizes its market position.
- Drug Development Progress: The company is advancing its lead PTSD drug candidate SPC-15, indicating a strategic focus on addressing the growing mental health market, which could lead to significant revenue opportunities.
- AI Platform Development: Silo Pharma is also developing its AI agents platform, QwikAgents, demonstrating its commitment to leveraging artificial intelligence to enhance drug development efficiency, potentially paving the way for future product innovations.
- Historical Financial Data: Historical financial data for Silo Pharma shows fluctuations in past performance, but the recent compliance regain may support future financing efforts and improve market performance.
See More
Silo Pharma Regains Nasdaq Compliance Status
- Compliance Restoration: Silo Pharma confirmed on June 17, 2026, that it has regained compliance with Nasdaq's minimum closing bid price requirement, marking a restoration of stability in the capital market and boosting investor confidence.
- Commitment to Shareholder Value: CEO Eric Weisblum stated that the company will continue to focus on creating long-term shareholder value, particularly in advancing the first-in-human clinical trial for PTSD and the AI platform QwikAgents.
- Innovative Drug Development: Silo Pharma is dedicated to developing therapeutic solutions for underserved medical needs, including SPC-15 for PTSD and SP-26 for fibromyalgia, showcasing the company's broad potential in the biopharmaceutical sector.
- Research Collaboration Network: The company conducts research in collaboration with leading universities and laboratories, further enhancing its innovative capabilities in areas such as central nervous system diseases, which is expected to drive future business growth.
See More
Federal Initiatives Propel Innovation in Mental Health Treatments
- Federal Funding Support: U.S. federal agencies are providing funding through the EVIDENT program to institutions like Johns Hopkins University, indicating a strong commitment to advancing mental health treatments, which is expected to accelerate the development of psychedelic therapeutics.
- FDA New Drug Approval: The FDA has granted investigational new drug clearance to DemeRx NB for its noribogaine candidate targeting alcohol use disorder, further propelling the expansion of clinical-stage programs in the mental health sector.
- Priority Treatment Programs: The FDA issued three National Priority Vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics, underscoring a focus on PTSD-related initiatives aimed at addressing urgent needs among veterans and broader patient populations.
- Guidance Release Imminent: The FDA confirmed that final guidance for psychedelic drug development will be published soon, a long-awaited milestone expected to provide critical clarity for sponsors and researchers navigating clinical and regulatory pathways, facilitating the development of a new generation of therapies.
See More
Silo Pharma Expands into AI Technology Business
- Strategic Business Expansion: Silo Pharma has announced the acquisition of Qwikagents.ai's assets, marking its entry into the AI technology sector, aiming to enhance business diversity by providing autonomous AI agents for task execution.
- Significant Market Potential: According to MarketsandMarkets.com, the AI agent market is projected to reach between $47 billion and $53 billion by 2030, indicating a growth of approximately six times in the next four years, showcasing substantial business opportunities.
- Core Therapeutic Focus: Silo Pharma concentrates on stress-induced psychiatric disorders, chronic pain, and central nervous system diseases, with existing products like SPC-15 for PTSD and SP-26 for Fibromyalgia, demonstrating a solid foundation in the biopharmaceutical sector.
- Notable Stock Volatility: SILO's stock has traded between $0.22 and $1.18 over the past year, closing at $0.56 on Wednesday with an 8.13% decline, and further dropping 7.67% to $0.52 in after-hours trading, reflecting market caution regarding its new strategic direction.
See More
Silo Pharma Advances Psychedelic Therapies for Mental Health
- Therapy Development: Silo Pharma announced plans to advance psychedelic-based therapies, particularly SPC-15 for treating post-traumatic stress disorder (PTSD), following an executive order issued by the U.S. government on April 18, 2026, aimed at accelerating research and patient access to mental health treatments.
- SPC-15 Overview: SPC-15 is a novel serotonin 4 (5-HT4) receptor agonist delivered via an intranasal system, allowing for rapid delivery to the central nervous system, thus providing effective prophylactic treatment for PTSD patients and showcasing its potential in the mental health sector.
- Regulatory Pathway: The program is being advanced under the 505(b)(2) regulatory pathway to streamline the development timeline, enabling the company to enter clinical trials more quickly, with plans to file an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA).
- Market Reaction: SILO shares closed at $0.51 on Friday, up 1.18%, and are trading at $0.52 in premarket, up 0.95%, indicating a positive market response to the company's new strategic direction.
See More
Silo Pharma Initiates SPC-15 Robustness Study
- Study Initiation: Silo Pharma has engaged Resyca to conduct a robustness study evaluating the performance and formulation stability of its microchip-based nasal spray system for SPC-15, laying the groundwork for upcoming human clinical trials.
- FDA Meeting Preparation: The data from this study is expected to support Silo Pharma's Type C meeting request with the FDA, seeking regulatory guidance on its IND strategy and Phase 1 clinical trial design, thereby advancing the product development process.
- Technological Advantage: Resyca's patented Soft-Mist Nasal Spray system is designed to effectively bypass the blood-brain barrier, and Silo believes this technology could enhance drug concentrations in the brain while reducing systemic exposure, potentially accelerating therapeutic onset and improving safety.
- Standard Testing: Robustness testing is a standard component of combination product development, and Silo's study will assess the formulation stability and device performance consistency of SPC-15 and its placebo over a 30-day period to ensure reliability before clinical evaluation.
See More
Silo Pharma Regains Nasdaq Compliance
- Compliance Regained: Silo Pharma announced on June 17 that it has regained compliance with Nasdaq's minimum bid price requirement, allowing its shares to continue trading on the Nasdaq Capital Market, which enhances investor confidence and stabilizes its market position.
- Drug Development Progress: The company is advancing its lead PTSD drug candidate SPC-15, indicating a strategic focus on addressing the growing mental health market, which could lead to significant revenue opportunities.
- AI Platform Development: Silo Pharma is also developing its AI agents platform, QwikAgents, demonstrating its commitment to leveraging artificial intelligence to enhance drug development efficiency, potentially paving the way for future product innovations.
- Historical Financial Data: Historical financial data for Silo Pharma shows fluctuations in past performance, but the recent compliance regain may support future financing efforts and improve market performance.
See More
Silo Pharma Regains Nasdaq Compliance Status
- Compliance Restoration: Silo Pharma confirmed on June 17, 2026, that it has regained compliance with Nasdaq's minimum closing bid price requirement, marking a restoration of stability in the capital market and boosting investor confidence.
- Commitment to Shareholder Value: CEO Eric Weisblum stated that the company will continue to focus on creating long-term shareholder value, particularly in advancing the first-in-human clinical trial for PTSD and the AI platform QwikAgents.
- Innovative Drug Development: Silo Pharma is dedicated to developing therapeutic solutions for underserved medical needs, including SPC-15 for PTSD and SP-26 for fibromyalgia, showcasing the company's broad potential in the biopharmaceutical sector.
- Research Collaboration Network: The company conducts research in collaboration with leading universities and laboratories, further enhancing its innovative capabilities in areas such as central nervous system diseases, which is expected to drive future business growth.
See More
Federal Initiatives Propel Innovation in Mental Health Treatments
- Federal Funding Support: U.S. federal agencies are providing funding through the EVIDENT program to institutions like Johns Hopkins University, indicating a strong commitment to advancing mental health treatments, which is expected to accelerate the development of psychedelic therapeutics.
- FDA New Drug Approval: The FDA has granted investigational new drug clearance to DemeRx NB for its noribogaine candidate targeting alcohol use disorder, further propelling the expansion of clinical-stage programs in the mental health sector.
- Priority Treatment Programs: The FDA issued three National Priority Vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics, underscoring a focus on PTSD-related initiatives aimed at addressing urgent needs among veterans and broader patient populations.
- Guidance Release Imminent: The FDA confirmed that final guidance for psychedelic drug development will be published soon, a long-awaited milestone expected to provide critical clarity for sponsors and researchers navigating clinical and regulatory pathways, facilitating the development of a new generation of therapies.
See More
Silo Pharma Expands into AI Technology Business
- Strategic Business Expansion: Silo Pharma has announced the acquisition of Qwikagents.ai's assets, marking its entry into the AI technology sector, aiming to enhance business diversity by providing autonomous AI agents for task execution.
- Significant Market Potential: According to MarketsandMarkets.com, the AI agent market is projected to reach between $47 billion and $53 billion by 2030, indicating a growth of approximately six times in the next four years, showcasing substantial business opportunities.
- Core Therapeutic Focus: Silo Pharma concentrates on stress-induced psychiatric disorders, chronic pain, and central nervous system diseases, with existing products like SPC-15 for PTSD and SP-26 for Fibromyalgia, demonstrating a solid foundation in the biopharmaceutical sector.
- Notable Stock Volatility: SILO's stock has traded between $0.22 and $1.18 over the past year, closing at $0.56 on Wednesday with an 8.13% decline, and further dropping 7.67% to $0.52 in after-hours trading, reflecting market caution regarding its new strategic direction.
See More
Silo Pharma Advances Psychedelic Therapies for Mental Health
- Therapy Development: Silo Pharma announced plans to advance psychedelic-based therapies, particularly SPC-15 for treating post-traumatic stress disorder (PTSD), following an executive order issued by the U.S. government on April 18, 2026, aimed at accelerating research and patient access to mental health treatments.
- SPC-15 Overview: SPC-15 is a novel serotonin 4 (5-HT4) receptor agonist delivered via an intranasal system, allowing for rapid delivery to the central nervous system, thus providing effective prophylactic treatment for PTSD patients and showcasing its potential in the mental health sector.
- Regulatory Pathway: The program is being advanced under the 505(b)(2) regulatory pathway to streamline the development timeline, enabling the company to enter clinical trials more quickly, with plans to file an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA).
- Market Reaction: SILO shares closed at $0.51 on Friday, up 1.18%, and are trading at $0.52 in premarket, up 0.95%, indicating a positive market response to the company's new strategic direction.
See More
